000			02423nam a22003617a 4500
008			210217s20202020 xxu||||| |||| 00| 0 eng d
024			_a10.4254/wjh.v12.i12.1341 [doi]
024			_aPMC7772723 [pmc]
040			_aOvid MEDLINE(R)
099			_a33442459
245			_aSafety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports.
251			_aWorld Journal of Hepatology. 12(12):1341-1348, 2020 Dec 27.
252			_aWorld J Hepatol. 12(12):1341-1348, 2020 Dec 27.
253			_aWorld journal of hepatology
260			_c2020
260			_fFY2021
265			_sppublish
266			_d2021-02-17
520			_aBACKGROUND: Direct-acting antiviral (DAA) therapy regimens are highly effective at eliminating hepatitis C virus (HCV) infection but rates of sustained virologic response (SVR) are lower in patients with decompensated cirrhosis or hepatocellular carcinoma. Since many of these patients will be referred for liver transplant, they will require retreatment after transplantation. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended by guidelines as the preferred regimen to treat HCV in DAA-experienced patients following liver transplant however there is limited data.
520			_aCASE SUMMARY: We present the cases of six liver transplant recipients who had previous treatment failure with sofosbuvir-based DAA therapy prior to transplantation and who then received SOF/VEL/VOX after transplant.
520			_aCONCLUSION: This case series demonstrate the real-world efficacy and safety of SOF/VEL/VOX in the post liver transplant setting. Treatment was successful with all patients achieving SVR, it was well tolerated, and there were minimal drug-drug interactions with their immunosuppressants. Copyright (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Medical Group
651			_aMedStar Washington Hospital Center
656			_aTransplant Hepatology Service
657			_aCase Reports
700			_aHigley, Cory
700			_aLalos, Alexander
790			_aHigley C, Hsu CC, Lalos AT, Nadella S, Smith C
856			_uhttps://dx.doi.org/10.4254/wjh.v12.i12.1341 _zhttps://dx.doi.org/10.4254/wjh.v12.i12.1341
942			_cART _dArticle
999			_c6112 _d6112